Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

NCT01696396
View directory record Official record
Conditions
Crohn's Disease
Interventions
Abrilumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 1Phase 2 Interventional

STA-5326 in Crohn's Disease Patients

NCT00088062
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Tucson, Arizona • Anaheim, California • North Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Not applicable Interventional Results available

A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders

NCT04247100
View directory record Official record
Conditions
Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder, Irritable Bowel Syndrome, Nausea, Dyspepsia
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS), Sham Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
Gisela Grotewold Chelimsky
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients

NCT03948854
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Registered dietitian, On-line video program, Printed handout, Dietitian-led group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

NCT00308581
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

NCT00038766
View directory record Official record
Conditions
Crohn Disease
Interventions
semapimod, placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
San Diego, California • Gainesville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated No phase listed Observational

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

NCT00707512
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
35
States / cities
Scottsdale, Arizona • Oceanside, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tilpisertib Fosmecarbil, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
35
States / cities
Sun City, Arizona • Chula Vista, California • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Efficacy of the Mediterranean Diet to the Low- Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Diet in Treating Irritable Bowel Syndrome(IBS)

NCT05807919
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Diet low in all FODMAP groups, Diet - Mediterranean
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas

NCT01145365
View directory record Official record
Conditions
Crohns Disease, Fistula, Abscess
Interventions
Exam under anesthesia (EUA)
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Risankizumab, Ustekinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
72
States / cities
Chandler, Arizona • Coronado, California • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

NCT03931330
View directory record Official record
Conditions
Functional Gastrointestinal Disorders, Irritable Bowel Syndrome, Dyspepsia, Functional Abdominal Pain Syndrome
Interventions
Percutaneous neurostimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

NCT00819663
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational

A Study of Surgical Interventions in Fistulizing Conditions

NCT04940611
View directory record Official record
Conditions
Crohns Disease, Fistula, Rectovaginal Fistula, Complex Perianal Fistula, Complex Cryptoglandular Fistula
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational

Characterization of CD Responders to Vedolizumab

NCT04909359
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Effects of a Novel Machine Learning Mobile App on Diet Adherence in Individuals Following the Low Fodmap Diet

NCT04256551
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Heali mobile application + Registered Dietitian, Heali mobile application, Standard Dietary Education
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

NCT00441766
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
AGN 203818, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02914522
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, PTM filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)

NCT01692743
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Home Monitoring
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting No phase listed Observational

Inflammatory Bowel Disease (IBD) Research Registry

NCT04243525
View directory record Official record
Conditions
Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Timeline
2009 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Irritable Bowel Syndrome and Food Sensitivity

NCT02186743
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Personalized Dietary Advice
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Family Members at INcreased-risk for Developing Inflammatory Bowel Disease

NCT06655415
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U), Indeterminate Colitis, Crohn's Disease Colon, Crohn's Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis, Ulcerative Proctitis, Ulcerative Proctosigmoiditis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 11:10 PM EDT